FLGT SHAREHOLDER ALERT: Jakubowitz Law Reminds Fulgent Shareholders of a Lead Plaintiff Deadline of November 21, 2022

NEW YORK, Oct. 28, 2022

To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/fulgent-genetics-inc-loss-submission-form/?id=33083&from=4

The lawsuit seeks to recover losses for shareholders who purchased Fulgent between March 22, 2019 and August 4, 2022.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until November 21, 2022 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, Fulgent Genetics, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (i) Fulgent had been conducting medically unnecessary laboratory testing, engaging in improper billing practices in relation to laboratory testing, and providing or receiving remuneration in violation of the Anti-Kickback Statute and Stark Law; (ii) accordingly, Fulgent was likely to become subject to enhanced legal and regulatory scrutiny; (iii) Fulgent's revenues, to the extent they were derived from the foregoing unlawful conduct, were unsustainable; (iv) the foregoing, once revealed, was likely to subject the Company to significant financial and/or reputational harm; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887